This video discusses new models for open innovation within the drug discovery and development industry. The discussion is led by Richard D. Klausner, Managing Partner of The Column Group."
Richard D. Klausner is Managing Partner of The Column Group, a venture capital fund focused on building the next generation of drug discovery and development companies. Dr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. Prior to that he served as Director of the National Cancer Institute from 1995 to 2001.
Dr. Klausner's research in hematology has been recognized with many awards, including the William Damashek Prize and the Outstanding Investigator Award of the American Federation of Clinical Research. He has served as an adviser to the Presidents of the National Academies for counter-terrorism and as a liaison to the White House Office of Science and Technology Policy. Dr. Klausner is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (seedialysis, prosthesis), and instruments for monitoring biological processes. Development has been particularly rapid in the area of artificial organs, which culminated in the implantation of an artificial heart into a human being in 1982. Bioengineers also develop equipment that enables humans to maintain body functions in hostile environments, such as the space suits worn by astronauts during extravehicular maneuvers.